These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31442252)

  • 1. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
    Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
    PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Nov; 208(2):415-427. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
    Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
    Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
    Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
    J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
    El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
    Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
    Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
    Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
    Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
    Chen J; Zhu Y; Wu W; Xu Y; Yang W; Ling L; Lin Q; Jia S; Xia Y; Liu Z; Yang Y; Gong C
    Oncologist; 2024 Jul; 29(7):e864-e876. PubMed ID: 38366907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.